Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors.

NCT04152018 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

85

Enrollment

INDUSTRY

Sponsor class

Stopped Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.

Conditions

Squamous Cell Carcinoma of the Head and Neck
Renal Cell Carcinoma
Ovarian Cancer
Gastric Cancer
Esophageal Cancer
Lung Squamous Cell Carcinoma
Pancreatic Cancer
Bile Duct Cancer
Endometrial Cancer
Melanoma Cancer
Urothelial Cancer

Interventions

DRUG: PF-06940434
DRUG: PF-06801591

Sponsor

Pfizer